Pfizer (PFE) DIvidends Date & History

Key Takeaways

• Pfizer maintains a quarterly dividend of $0.43 per share, delivering an annual payout of $1.72 and a current yield of approximately 7.15%.
• The company has paid consecutive quarterly dividends for 349 periods and increased its dividend for 17 straight years.
• The trailing payout ratio stands near 131%, indicating dividends exceed recent earnings but remain supported by free cash flow.
• Pfizer’s yield significantly exceeds the pharmaceutical sector average, appealing to income-focused investors.
• Next ex-dividend date is July 24, 2026, with payment scheduled for September 1, 2026.
• Long-term dividend sustainability depends on earnings recovery and cash generation amid post-pandemic revenue normalization.

Dividend Overview

Pfizer Inc. (PFE) follows a consistent quarterly dividend policy, distributing $0.43 per share four times annually for a total of $1.72. This produces a yield near 7.15% based on recent share prices. The company qualifies as a high-yield dividend stock within the pharmaceutical sector rather than a rapid dividend-growth name. Payments have remained steady through multiple economic cycles, reflecting management’s commitment to returning capital to shareholders while funding research and development.

Dividend History and Growth

Pfizer has maintained an uninterrupted streak of quarterly dividends dating back decades, reaching its 349th consecutive payment in 2026. Annual increases have occurred for 17 consecutive years, though recent growth rates have moderated to low single digits. The dividend has risen gradually from lower levels in prior decades, supported by robust cash flows from blockbuster products. No cuts have occurred in the modern era, underscoring a conservative approach to dividend policy even during periods of revenue transition.

Dividend Sustainability and Payout Ratio

The current payout ratio of roughly 131% exceeds 100%, meaning dividends surpass trailing twelve-month earnings. This level warrants monitoring, yet Pfizer’s substantial free cash flow historically provides adequate coverage. Debt remains manageable relative to cash generation, and the company maintains a strong balance sheet. Long-term sustainability will hinge on successful pipeline execution and cost discipline following the decline in COVID-19-related revenues. Investors should watch upcoming earnings reports for signs of earnings stabilization.

Dividend Compared to Industry Peers

Pfizer’s approximately 7.15% yield stands well above the pharmaceutical sector median and exceeds peers such as Bristol Myers Squibb (BMY), which offers a yield near 4.36%. While many large-cap pharma companies deliver modest yields with lower payout ratios, Pfizer provides higher current income. This positions the stock as a higher-yielding option within the group, though peers may offer stronger near-term earnings coverage.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener.

Is This Stock Attractive for Dividend Investors?

Pfizer may appeal to income-oriented investors seeking elevated current yields within the healthcare sector. The stock suits those comfortable with a payout ratio above 100% in exchange for higher distributions and a lengthy payment history. Dividend-growth investors might find the modest recent increases less compelling compared with faster-growing names. Conservative long-term holders could value the company’s scale and diversified pipeline as buffers against volatility. The elevated yield reflects market pricing of post-pandemic revenue normalization rather than imminent distress. Prospective investors should evaluate full financial statements and consider personal risk tolerance before committing capital.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.